SNOA — Stock Film
STOCK FILMSCENE 1/11SNOA · $1.34
Stock Expert AI presents
SNOA
Sonoma Pharmaceuticals, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Sonoma Pharmaceuticals, Inc. A quick introduction.

On the stock market since 2007, it operates in the world of health and science. It has 10 employees. Now — the numbers.

on the stock market since 2007
10 employees
$1.9M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.2.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

WHERE DOES THE MONEY COME FROM?
91%Human Care
Human Care 91%Animal Care 9%
91% of all revenue comes from a single line: Human Care.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.

$12.6M
2022
$13.3M
2023
$12.7M
2024
$14.3M
2025
$19.5M
2026
In the vault right now:
$0
DEBT: $842K
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
47
weak

Clearly below the class average.

FINANCIAL STRENGTH
22
very weak

Clearly below the class average.

VALUATION
58
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
43
weak

Clearly below the class average.

PRICE MOMENTUM
22
very weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 14% a year on average.

2
THE BRIGHT SIDE · 2/3
The product is selling

Sales run at $19.5M a year. A small number, but proof the product has real buyers.

3
THE BRIGHT SIDE · 3/3
Executives are buying their own stock

Over the last 12 months, company executives reported 16 buys and 0 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Running at a loss

A loss of $3.2M against $19.5M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, SNOA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: SNOA is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film